Patients with STEMI who underwent primary PCI had better clinical outcomes — and no greater risk for bleeding — with a 600-mg loading dose compared with 300 mg. Given that platelet inhibition ...

Are there additional risks of toxicity (or more acute development of toxicity) associated with aggressive loading doses? Are differences in efficacy and/or toxicity due to differing generic products?

Does timing of an atorvastatin loading dose make a difference in PCI for ACS? C. Michael Gibson and Renato Lopes discuss.